{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:17:13Z","timestamp":1788830233769,"version":"build-2803163510"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001466","name":"American Urological Association Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001466","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.prostaglandins.2020.106409","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T11:58:54Z","timestamp":1578657534000},"page":"106409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Prostaglandin E2 as a therapeutic target in bladder cancer: From basic science to clinical trials"],"prefix":"10.1016","volume":"148","author":[{"given":"Benjamin L.","family":"Woolbright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol C.","family":"Pilbeam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10061","key":"10.1016\/j.prostaglandins.2020.106409_bib0005","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0010","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/0970-1591.203419","article-title":"Bladder cancer: 2017 and beyond","volume":"33","author":"Kamat","year":"2017","journal-title":"Indian J. Urol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106409_bib0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/BLC-170118","article-title":"Once BCG unresponsive, always BCG unresponsive: an open letter to the FDA to enhance recruitment into clinical trials in bladder cancer","volume":"3","author":"Kamat","year":"2017","journal-title":"Bladder Cancer"},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00281-012-0342-8","article-title":"Multifaceted roles of PGE2 in inflammation and cancer","volume":"35","author":"Nakanishi","year":"2013","journal-title":"Semin. Immunopathol."},{"issue":"1-2","key":"10.1016\/j.prostaglandins.2020.106409_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.prostaglandins.2008.09.003","article-title":"Regulation of the prostaglandin pathway during development of invasive bladder cancer in mice","volume":"88","author":"Taylor","year":"2009","journal-title":"Prostaglandins Lipid Mediat."},{"issue":"7","key":"10.1016\/j.prostaglandins.2020.106409_bib0030","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1054\/bjoc.1999.1106","article-title":"Non-steroidal anti-inflammatory drugs and bladder cancer prevention","volume":"82","author":"Castelao","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.prostaglandins.2020.106409_bib0035","doi-asserted-by":"crossref","first-page":"e70008","DOI":"10.1371\/journal.pone.0070008","article-title":"Use of nonsteroidal anti-inflammatory drugs and bladder cancer risk: a meta-analysis of epidemiologic studies","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ijc.31290","article-title":"Arsenic promotes the COX2\/PGE2-SOX2 axis to increase the malignant stemness properties of urothelial cells","volume":"143","author":"Ooki","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0045","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1158\/0008-5472.CAN-17-0836","article-title":"YAP1 and COX2 coordinately regulate urothelial cancer Stem-like cells","volume":"78","author":"Ooki","year":"2018","journal-title":"Cancer Res."},{"issue":"7533","key":"10.1016\/j.prostaglandins.2020.106409_bib0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature14034","article-title":"Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance","volume":"517","author":"Kurtova","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/bjc.2017.393","article-title":"Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression","volume":"118","author":"Kashiwagi","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.prostaglandins.2020.106409_bib0060","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/1535-7163.MCT-10-0049","article-title":"Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder","volume":"9","author":"Dhawan","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106409_bib0065","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1535-7163.MCT-07-0313","article-title":"Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells","volume":"7","author":"Dhawan","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/1535-7163.MCT-05-0117","article-title":"Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects","volume":"5","author":"Mohammed","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.prostaglandins.2020.106409_bib0075","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/ijc.2910550622","article-title":"Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model","volume":"55","author":"Shibata","year":"1993","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106409_bib0080","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/jpet.108.138776","article-title":"MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation","volume":"326","author":"Xu","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106409_bib0085","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1530\/ERC-15-0277","article-title":"mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity","volume":"22","author":"Finetti","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0090","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.urology.2005.02.024","article-title":"NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation","volume":"66","author":"Smakman","year":"2005","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.prostaglandins.2020.106409_bib0095","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.urolonc.2012.06.001","article-title":"Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and Lifestyle (VITAL) study","volume":"31","author":"Shih","year":"2013","journal-title":"Urol. Oncol."},{"issue":"7","key":"10.1016\/j.prostaglandins.2020.106409_bib0100","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/aje\/kwq437","article-title":"Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis","volume":"173","author":"Daugherty","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.prostaglandins.2020.106409_bib0105","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/annonc\/mds113","article-title":"Aspirin and cancer risk: a quantitative review to 2011","volume":"23","author":"Bosetti","year":"2012","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106409_bib0110","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.eururo.2018.09.020","article-title":"BOXIT-a randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK\/07\/004)","volume":"75","author":"Kelly","year":"2019","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0115","doi-asserted-by":"crossref","first-page":"4-","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.prostaglandins.2020.106409_bib0120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/nrd1225","article-title":"COX-2 and beyond: approaches to prostaglandin inhibition in human disease","volume":"2","author":"FitzGerald","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.prostaglandins.2020.106409_bib0125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","article-title":"Cyclooxygenases: structural, cellular, and molecular biology","volume":"69","author":"Smith","year":"2000","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14728214.8.1.1","article-title":"The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer","volume":"8","author":"Crosby","year":"2003","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.prostaglandins.2020.106409_bib0135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.53.082901.103952","article-title":"Cyclooxygenase-2: a therapeutic target","volume":"53","author":"Turini","year":"2002","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106409_bib0140","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00002018-200528030-00001","article-title":"Do selective cyclo-oxygenase-2 inhibitors have a future?","volume":"28","author":"Bannwarth","year":"2005","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106409_bib0145","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bcp.13048","article-title":"Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective","volume":"82","author":"Patrono","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.prostaglandins.2020.106409_bib0150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0090-6980(02)00043-6","article-title":"Prostaglandin e synthase","volume":"68\u201369","author":"Murakami","year":"2002","journal-title":"Prostaglandins Lipid Mediat."},{"issue":"12","key":"10.1016\/j.prostaglandins.2020.106409_bib0155","first-page":"3971","article-title":"Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer","volume":"7","author":"Yoshimatsu","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"39","key":"10.1016\/j.prostaglandins.2020.106409_bib0160","doi-asserted-by":"crossref","first-page":"14507","DOI":"10.1073\/pnas.0606586103","article-title":"Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis","volume":"103","author":"Wang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.prostaglandins.2020.106409_bib0165","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nn1137","article-title":"Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis","volume":"6","author":"Engblom","year":"2003","journal-title":"Nat. Neurosci."},{"issue":"22","key":"10.1016\/j.prostaglandins.2020.106409_bib0170","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1111\/bph.13331","article-title":"Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?","volume":"172","author":"O\u2019Callaghan","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1248\/bpb.b15-00840","article-title":"The roles of EP4 prostanoid receptors in cancer malignancy signaling","volume":"39","author":"Fujino","year":"2016","journal-title":"Biol. Pharm. Bull."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106409_bib0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1054\/plef.2000.0144","article-title":"Prostanoid receptors in intestinal epithelium: selective expression, function, and change with inflammation","volume":"63","author":"Takafuji","year":"2000","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"10.1016\/j.prostaglandins.2020.106409_bib0185","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0090-6980(02)00054-0","article-title":"Prostanoid receptor subtypes","volume":"68\u201369","author":"Tsuboi","year":"2002","journal-title":"Prostaglandins Other Lipid Mediat."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106409_bib0190","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jvim.13948","article-title":"A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis","volume":"30","author":"Rausch-Derra","year":"2016","journal-title":"J. Vet. Intern. Med."},{"issue":"5","key":"10.1016\/j.prostaglandins.2020.106409_bib0195","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.bmcl.2017.01.067","article-title":"Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist","volume":"27","author":"Okumura","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.prostaglandins.2020.106409_bib0200","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1021\/acs.jmedchem.5b00567","article-title":"A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques","volume":"58","author":"Fox","year":"2015","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.prostaglandins.2020.106409_bib0205","first-page":"3167","article-title":"Production of prostaglandin E2 by tumor cells in vitro","volume":"40","author":"Owen","year":"1980","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0210","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/carcin\/12.1.35","article-title":"Uracil-induced calculi and carcinogenesis in the urinary bladder of rats treated simultaneously with N-butyl-N-(4-hydroxybutyl)nitrosamine","volume":"12","author":"Okumura","year":"1991","journal-title":"Carcinogenesis"},{"issue":"4 Pt 1","key":"10.1016\/j.prostaglandins.2020.106409_bib0215","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0022-5347(05)64522-3","article-title":"Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer","volume":"168","author":"Wheeler","year":"2002","journal-title":"J. Urol."},{"issue":"5118","key":"10.1016\/j.prostaglandins.2020.106409_bib0220","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/216868a0","article-title":"Prostaglandins: their disappearance from and release into the circulation","volume":"216","author":"Ferreira","year":"1967","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106409_bib0225","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0302-2838(03)00313-0","article-title":"A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder","volume":"44","author":"Eschwege","year":"2003","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.prostaglandins.2020.106409_bib0230","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.urolonc.2007.05.015","article-title":"Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells","volume":"26","author":"Gee","year":"2008","journal-title":"Urol. Oncol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106409_bib0235","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2008.01.013","article-title":"Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma","volume":"54","author":"Dovedi","year":"2008","journal-title":"Eur. Urol."},{"issue":"14","key":"10.1016\/j.prostaglandins.2020.106409_bib0240","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1096\/fj.01-0299fje","article-title":"COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib","volume":"15","author":"Grosch","year":"2001","journal-title":"FASEB J."},{"issue":"21","key":"10.1016\/j.prostaglandins.2020.106409_bib0245","first-page":"6045","article-title":"Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models","volume":"60","author":"Williams","year":"2000","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0250","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.urolonc.2009.01.016","article-title":"Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor","volume":"28","author":"D\u2019Arca","year":"2010","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0255","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1940-6207.CAPR-13-0164","article-title":"Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model","volume":"7","author":"Nicastro","year":"2014","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0260","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/1940-6207.CAPR-13-0288","article-title":"Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K","volume":"7","author":"Kim","year":"2014","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"8","key":"10.1016\/j.prostaglandins.2020.106409_bib0265","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jnci\/94.8.585","article-title":"Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells","volume":"94","author":"Song","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106409_bib0270","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.prostaglandins.2020.106409_bib0275","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djj206","article-title":"Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors","volume":"98","author":"Grosch","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106409_bib0280","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.110.069393","article-title":"Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation","volume":"79","author":"Yu","year":"2011","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106409_bib0285","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canlet.2012.10.030","article-title":"Celecoxib antagonizes the cytotoxic effect of cisplatin in human gastric cancer cells by decreasing intracellular cisplatin accumulation","volume":"329","author":"Chen","year":"2013","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.prostaglandins.2020.106409_bib0290","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/15384047.2015.1099769","article-title":"Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance","volume":"16","author":"Webb","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"9","key":"10.1016\/j.prostaglandins.2020.106409_bib0295","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/ijc.23315","article-title":"Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells","volume":"122","author":"Xiao","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.prostaglandins.2020.106409_bib0300","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/1940-6207.CAPR-11-0036","article-title":"A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer","volume":"4","author":"Sabichi","year":"2011","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"7","key":"10.1016\/j.prostaglandins.2020.106409_bib0305","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrurol.2014.129","article-title":"Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer","volume":"11","author":"Choi","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.prostaglandins.2020.106409_bib0310","article-title":"The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability","author":"Kim","year":"2019","journal-title":"Eur. Urol."},{"issue":"9","key":"10.1016\/j.prostaglandins.2020.106409_bib0315","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/2159-8290.CD-12-0101","article-title":"Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling","volume":"2","author":"Li","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.prostaglandins.2020.106409_bib0320","doi-asserted-by":"crossref","first-page":"165879","DOI":"10.1155\/2012\/165879","article-title":"Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer","volume":"2012","author":"Thanan","year":"2012","journal-title":"Mediators Inflamm."},{"issue":"19","key":"10.1016\/j.prostaglandins.2020.106409_bib0325","doi-asserted-by":"crossref","first-page":"28235","DOI":"10.18632\/oncotarget.8595","article-title":"Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2\/PGE2\/STAT3 axis","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106409_bib0330","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.tiv.2013.01.012","article-title":"Sodium arsenite induces cyclooxygenase-2 expression in human uroepithelial cells through MAPK pathway activation and reactive oxygen species induction","volume":"27","author":"Wang","year":"2013","journal-title":"Toxicol. In Vitro"},{"issue":"6","key":"10.1016\/j.prostaglandins.2020.106409_bib0335","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/icb.2011.75","article-title":"Prostaglandin E2 and T cells: friends or foes?","volume":"90","author":"Sreeramkumar","year":"2012","journal-title":"Immunol. Cell Biol."},{"issue":"5","key":"10.1016\/j.prostaglandins.2020.106409_bib0340","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1073\/pnas.72.5.1848","article-title":"Subversion of immune system by tumor cells and role of prostaglandins","volume":"72","author":"Plescia","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.prostaglandins.2020.106409_bib0345","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/eji.1830181121","article-title":"Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells","volume":"18","author":"Rincon","year":"1988","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106409_bib0350","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4049\/jimmunol.139.4.1179","article-title":"Regulation of interleukin 2 synthesis by cAMP in human T cells","volume":"139","author":"Mary","year":"1987","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.prostaglandins.2020.106409_bib0355","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1073\/pnas.86.10.3803","article-title":"Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2","volume":"86","author":"Hart","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0360","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4049\/jimmunol.146.1.108","article-title":"Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines","volume":"146","author":"Betz","year":"1991","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106409_bib0365","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4049\/jimmunol.175.3.1483","article-title":"Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells","volume":"175","author":"Baratelli","year":"2005","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.prostaglandins.2020.106409_bib0370","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/0008-5472.CAN-05-0141","article-title":"Tumor cyclooxygenase-2\/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer","volume":"65","author":"Sharma","year":"2005","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.prostaglandins.2020.106409_bib0375","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1073\/pnas.1612920114","article-title":"COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells","volume":"114","author":"Prima","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.prostaglandins.2020.106409_bib0380","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1158\/0008-5472.CAN-06-4174","article-title":"Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells","volume":"67","author":"Sinha","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.prostaglandins.2020.106409_bib0385","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0090-6980(97)00161-5","article-title":"In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer","volume":"54","author":"Wang","year":"1997","journal-title":"Prostaglandins"},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0390","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2249.2002.01686.x","article-title":"Prostaglandin E2 down-regulates viable Bacille Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro","volume":"128","author":"Yamada","year":"2002","journal-title":"Clin. Exp. Immunol."},{"issue":"15","key":"10.1016\/j.prostaglandins.2020.106409_bib0395","doi-asserted-by":"crossref","first-page":"14433","DOI":"10.1074\/jbc.M410725200","article-title":"Prostaglandin E2 induces interleukin-8 gene transcription by activating C\/EBP homologous protein in human T lymphocytes","volume":"280","author":"Caristi","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.prostaglandins.2020.106409_bib0400","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"23","key":"10.1016\/j.prostaglandins.2020.106409_bib0405","doi-asserted-by":"crossref","first-page":"24866","DOI":"10.1074\/jbc.M403106200","article-title":"Carrageenan-induced paw edema in rat elicits a predominant prostaglandin E2 (PGE2) response in the central nervous system associated with the induction of microsomal PGE2 synthase-1","volume":"279","author":"Guay","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.prostaglandins.2020.106409_bib0410","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1158\/1940-6207.CAPR-11-0188","article-title":"Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity","volume":"4","author":"Nakanishi","year":"2011","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"6","key":"10.1016\/j.prostaglandins.2020.106409_bib0415","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.biochi.2010.02.006","article-title":"mPGES-1 as a target for cancer suppression: A comprehensive invited review \"Phospholipase A2 and lipid mediators\"","volume":"92","author":"Nakanishi","year":"2010","journal-title":"Biochimie"},{"issue":"22","key":"10.1016\/j.prostaglandins.2020.106409_bib0420","doi-asserted-by":"crossref","first-page":"23229","DOI":"10.1074\/jbc.M400443200","article-title":"Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile","volume":"279","author":"Boulet","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.prostaglandins.2020.106409_bib0425","doi-asserted-by":"crossref","first-page":"16579","DOI":"10.1074\/jbc.M412075200","article-title":"Redirection of eicosanoid metabolism in mPGES-1-deficient macrophages","volume":"280","author":"Trebino","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prostaglandins.2020.106409_bib0430","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.prostaglandins.2013.04.002","article-title":"Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis","volume":"106","author":"Howe","year":"2013","journal-title":"Prostaglandins Lipid Mediat."},{"issue":"9","key":"10.1016\/j.prostaglandins.2020.106409_bib0435","first-page":"2669","article-title":"Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer","volume":"7","author":"Yoshimatsu","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.prostaglandins.2020.106409_bib0440","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s00428-004-1104-3","article-title":"Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis","volume":"445","author":"Jang","year":"2004","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0445","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/gut.53.1.27","article-title":"Expression of cyclooxygenase 2, microsomal prostaglandin E synthase 1, and EP receptors is increased in rat oesophageal squamous cell dysplasia and Barrett\u2019s metaplasia induced by duodenal contents reflux","volume":"53","author":"Jang","year":"2004","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.prostaglandins.2020.106409_bib0450","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.plefa.2006.02.005","article-title":"Elevated prostaglandin E2 level via cPLA2--COX-2--mPGES-1 pathway involved in bladder carcinogenesis induced by terephthalic acid-calculi in Wistar rats","volume":"74","author":"Shi","year":"2006","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"issue":"9","key":"10.1016\/j.prostaglandins.2020.106409_bib0455","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/0008-5472.CAN-07-6100","article-title":"Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis","volume":"68","author":"Nakanishi","year":"2008","journal-title":"Cancer Res."},{"issue":"44","key":"10.1016\/j.prostaglandins.2020.106409_bib0460","doi-asserted-by":"crossref","first-page":"18757","DOI":"10.1073\/pnas.0910218106","article-title":"Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells","volume":"106","author":"Hanaka","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15\u201316","key":"10.1016\/j.prostaglandins.2020.106409_bib0465","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.lfs.2011.02.008","article-title":"Microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice","volume":"88","author":"Isono","year":"2011","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0470","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1038\/s41598-018-23482-4","article-title":"Structure-based discovery of mPGES-1 inhibitors suitable for preclinical testing in wild-type mice as a new generation of anti-inflammatory drugs","volume":"8","author":"Ding","year":"2018","journal-title":"Sci. Rep."},{"issue":"6240","key":"10.1016\/j.prostaglandins.2020.106409_bib0475","doi-asserted-by":"crossref","first-page":"aaa2340","DOI":"10.1126\/science.aaa2340","article-title":"TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration","volume":"348","author":"Zhang","year":"2015","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.prostaglandins.2020.106409_bib0480","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/onc.2013.69","article-title":"15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2\/PPARgamma-mediated activation of p21WAF1\/Cip1","volume":"33","author":"Lu","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0485","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1038\/s41598-019-41862-2","article-title":"miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer","volume":"9","author":"Monteleone","year":"2019","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.prostaglandins.2020.106409_bib0490","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1158\/0008-5472.CAN-08-4043","article-title":"Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro","volume":"69","author":"Dyrskjot","year":"2009","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0495","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.urolonc.2008.06.006","article-title":"A microRNA expression ratio defining the invasive phenotype in bladder tumors","volume":"28","author":"Neely","year":"2010","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.prostaglandins.2020.106409_bib0500","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/1940-6207.CAPR-12-0358","article-title":"Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo","volume":"6","author":"Cekanova","year":"2013","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0505","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1186\/s12885-018-4409-3","article-title":"Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq","volume":"18","author":"Maeda","year":"2018","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.prostaglandins.2020.106409_bib0510","first-page":"952","article-title":"Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer","volume":"4","author":"von der Emde","year":"2014","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106409_bib0515","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/cts.12497","article-title":"LY3127760, a selective prostaglandin E4 (EP4) receptor antagonist, and celecoxib: a comparison of pharmacological profiles","volume":"11","author":"Jin","year":"2018","journal-title":"Clin. Transl. Sci."}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882320300022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882320300022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:00:39Z","timestamp":1761098439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882320300022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":103,"alternative-id":["S1098882320300022"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2020.106409","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostaglandin E2 as a therapeutic target in bladder cancer: From basic science to clinical trials","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2020.106409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106409"}}